IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines

GENEVA – 26 June 2019 – The International Generic and Biosimilar medicines Association (IGBA) today released a revised report Trade Principles: Generic and Biosimilar Medicines which addresses how trade agreements can be designed to foster trade in generic and biosimilar medicines and improve access to affordable medicines.


Committing to Global Health: Balancing Access and Sustainability key to success

Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition, regulatory convergence, biosimilar medicines uptake and continuous innovation will deliver efficiency for healthcare, improved access to medicines and opportunities for manufacturers to invest for the future.   


Contribution of the generic and biosimilar medicines industries to the 2030 United Nations Agenda for Sustainable Development - Universal Health Coverage

Geneva, 20 May 2019 - Generic and biosimilar medicines have improved the quality of life of patients all over the world by increasing access to high-quality medicines. It is useful to report data that shows the actual impact of generic and biosimilar medicines in everyday life.

Contact Info


Rue des Pierres-du-Niton 17
1207 Geneva

Telephone: +32 (0)2 5346607
This email address is being protected from spambots. You need JavaScript enabled to view it.  
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site